Further, pseudodehydrocorydaline (a protoberberine alkaloid) selectively suppresses the activity of HMT G9a and decreases the expression of H3K9me2 in MCF-7 breast cancer cells via CT13 occupation of the binding site of histone H3, suggesting that CT13 might provide a novel scaffold for synthetic G9a inhibitors (135). This evidence concerns the gene EHMT2 and breast carcinoma.